Comparison of risk models for mortality and cardiovascular events between machine learning and conventional logistic regression analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 11 06 2019
accepted: 16 08 2019
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 7 3 2020
Statut: epublish

Résumé

Non-linear models by machine learning may identify different risk factors with different weighting in comparison to conventional linear models. The analyses were performed in 15,933 patients included in the Shinken Database (SD) 2004-2014 (n = 22,022) for whom baseline data of blood sampling and ultrasound cardiogram and follow-up data at 2 years were available. Using non-linear models with machine learning software, 118 risk factors and their weighting of risk for all-cause mortality, heart failure (HF), acute coronary syndrome (ACS), ischemic stroke (IS), and intracranial hemorrhage (ICH) were identified, where the top two risk factors were albumin/hemoglobin, left ventricular ejection fraction/history of HF, history of ACS/anti-platelet use, history of IS/deceleration time, and history of ICH/warfarin use. The areas under the curve of the developed models for each event were 0.900, 0.912, 0.879, 0.758, and 0.753, respectively. Here, we described our experience with the development of models for predicting cardiovascular prognosis by machine learning. Machine learning could identify risk predicting models with good predictive capability and good discrimination of the risk impact.

Identifiants

pubmed: 31499517
doi: 10.1371/journal.pone.0221911
pii: PONE-D-19-16602
pmc: PMC6733605
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221911

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

Dr. Suzuki received research funding from Mitsubishi Tanabe Pharm, and Daiichi Sankyo. Dr. Yamashita has received research funds and/or lecture fees from Daiichi Sankyo, Bayer Yakuhin, Bristol-Myers Squibb, Pfizer, Nippon Boehringer Ingelheim, Eisai, Mitsubishi Tanabe Pharm, Ono Pharmaceutical, and Toa Eiyo. These do not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Clin Cardiol. 2019 Mar;42(3):365-372
pubmed: 30637771
J Am Geriatr Soc. 2013 Sep;61(9):1499-507
pubmed: 24006851
Int J Cardiol. 2017 Jul 1;238:151-158
pubmed: 28341375
BMC Med Inform Decis Mak. 2010 Mar 22;10:16
pubmed: 20307319
Circulation. 1991 Jan;83(1):356-62
pubmed: 1984895
Stat Med. 1998 Nov 15;17(21):2501-8
pubmed: 9819841
Circ J. 2008 Jun;72(6):914-20
pubmed: 18503216
PLoS One. 2018 Mar 1;13(3):e0193511
pubmed: 29494637
Circulation. 2015 Nov 17;132(20):1920-30
pubmed: 26572668
Circ Heart Fail. 2017 Jul;10(7):
pubmed: 28701328
ESC Heart Fail. 2019 Apr;6(2):396-405
pubmed: 30706996
Biomed Mater Eng. 2014;24(6):2963-9
pubmed: 25227003
Am J Cardiol. 1976 Jul;38(1):46-51
pubmed: 132862
Int J Cardiol. 2016 Sep 15;219:20-4
pubmed: 27257851
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1127-35
pubmed: 26581149
PLoS One. 2017 Apr 4;12(4):e0174944
pubmed: 28376093
Clin Chim Acta. 2018 Feb;477:89-93
pubmed: 29241048
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1109-1117
pubmed: 28490436
Int J Cardiol. 2019 Jul 1;286:43-50
pubmed: 30846254
IEEE Trans Pattern Anal Mach Intell. 2009 Feb;31(2):210-27
pubmed: 19110489
IEEE Trans Neural Netw. 1999;10(5):988-99
pubmed: 18252602
Int J Cardiol. 2016 Nov 15;223:647-648
pubmed: 27567231
N Engl J Med. 2017 Jun 29;376(26):2507-2509
pubmed: 28657867
Circ J. 2019 Feb 25;83(3):614-621
pubmed: 30700666
J Cardiol. 2011 Sep;58(2):116-23
pubmed: 21820280
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Comput Math Methods Med. 2016;2016:3016245
pubmed: 27594895
Ann Intern Med. 2017 Nov 21;167(10):698-705
pubmed: 28973663
Crit Care Med. 2006 May;34(5):1297-310
pubmed: 16540951
Clin Chem. 2017 Feb;63(2):477-485
pubmed: 27737895

Auteurs

Shinya Suzuki (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Takeshi Yamashita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Tsuyoshi Sakama (T)

Sigmaxyz, Inc, Tokyo, Japan.

Takuto Arita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Naoharu Yagi (N)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Takayuki Otsuka (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Hiroaki Semba (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Hiroto Kano (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Shunsuke Matsuno (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Yuko Kato (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Tokuhisa Uejima (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Yuji Oikawa (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Minoru Matsuhama (M)

Department of Cardiovascular Surgery, The Cardiovascular Institute, Tokyo, Japan.

Junji Yajima (J)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH